Biogen Q1 Earnings Call Highlights

Key Points

• Q1 results and strategic shift: Biogen reported revenue of $2.5 billion (up 2% YoY) and GAAP EPS of $2.15 (up 31%), saying it has reallocated spending away from legacy MS products toward growth drugs, which generated about $851 million in Q1 revenue (up 12% YoY).
• Commercial momentum: Leqembi sales surged 74% to $168 million and remained the market leader in key markets while SKYCLARYS grew 22% to $151 million as Biogen expands ex‑U.S. launches and prepares for an upcoming IQLIK PDUFA decision.
• Apellis acquisition and financial impact: The Apellis deal is expected to close in Q2 2026, funded with $3.6 billion cash and $2 billion in borrowings, will add Syfovre and Empaveli, is forecast to be accretive in 2027, and should impose a ~$120–$130 million hit to 2026 non‑GAAP other income/expense.

Biogen NASDAQ: BIIB executives pointed to a “very strong start” to 2026, highlighting growth in key products, progress across the late-stage pipeline, and preparations for the pending acquisition of Apellis Pharmaceuticals during the company’s first-quarter earnings call.

President and CEO Christopher Viehbacher said Biogen has moved from years of declining revenue and profit to stabilizing the business, emphasizing that the company has reallocated spending toward growth rather than relying solely on cost reductions. He noted that in 2023, roughly 90% of commercial spending supported the multiple sclerosis (MS) portfolio, but the company has since shifted resources toward growth products. Viehbacher said growth products generated about $850 million in Q1 revenue, up 12% year-over-year, while acknowledging Spinraza declined slightly due to shipment timing and a prior-year VAT-related item.

First-quarter financial results and guidance updates

Chief Financial Officer Robin Kramer reported total revenue of $2.5 billion, up 2% year-over-year. GAAP diluted EPS was $2.15, up 31%, and non-GAAP diluted EPS was $3.57, up 18%.

Kramer said growth products generated $851 million in Q1 revenue, up 12%, and that growth products (including Vumerity) generated more revenue than Biogen’s remaining MS products during the quarter. The company posted approximately $1.1 billion of non-GAAP core operating expenses and generated $594 million of free cash flow. Biogen ended the quarter with $4.7 billion in cash and marketable securities and $1.5 billion of net debt.

On expenses, Kramer said non-GAAP R&D expense was $480 million, reflecting investments in phase III programs including felzartamab and litifilimab, as well as phasing. Non-GAAP SG&A was $600 million, reflecting pre-launch activities for lupus and nephrology, direct-to-consumer advertising for Vumerity and ZURZUVAE, and phasing. The GAAP and non-GAAP effective tax rates were 15.4% and 15.3%, respectively, with the year-over-year decrease tied to a foreign tax settlement and vesting of certain share-based awards, partially offset by higher U.S. taxation on foreign earnings in 2026 under the “One Big Beautiful Bill Act.”

Biogen recorded approximately $34 million of acquired IPR&D in Q1 related primarily to the Alcyone and Alloy transaction, which Kramer said had an approximately $0.20 per share impact to GAAP and non-GAAP EPS. For Q2, Kramer said Biogen expects $145 million of acquired IPR&D charges, or an $0.80 EPS impact, including an expected $0.55 impact tied to the TJ Biopharma transaction for felzartamab rights in China and an expected $0.25 impact from a milestone triggered by dosing the first patient in the pivotal STELLAR-1 salanersen study.

Kramer said the company’s underlying business outlook remains consistent with February guidance, including its revenue outlook, and reiterated that roughly $600 million of contract manufacturing revenue is expected in 2026, with about two-thirds in the first half. She added that, based on potential tariffs announced to date, Biogen does not expect a material impact to its 2026 business (excluding the pending Apellis acquisition).

Commercial performance: Leqembi and SKYCLARYS

Kramer said Leqembi end market revenue was $168 million in Q1, up 74% year-over-year, with sequential market growth in the U.S., Japan, and China. She said Q1 China revenue benefited from completing a drawdown of inventory in Q4 2025. Kramer added that Leqembi remained the market leader by total patient share in the U.S., Japan, and China, and Biogen is looking toward a May U.S. PDUFA date for IQLIK initiation.

Head of Development Dr. Priya Singhal highlighted new real-world data for Leqembi showing persistence, with “nearly 80%” of patients remaining on therapy at 18 months and “almost 70%” at two years, which she said underscores the importance that patients and healthcare providers place on continued treatment.

SKYCLARYS posted Q1 global revenue of $151 million, representing 22% growth year-over-year, according to Kramer, who said the company saw sequential global patient demand growth. She noted U.S. revenue was impacted by inventory dynamics discussed on the prior quarter’s call, while demand outside the U.S. continued to grow as the global launch progresses. SKYCLARYS is now available in 35 countries, and Kramer said the company continues to expect growth to come from ex-U.S. markets.

During Q&A, North America President Alisha Alaimo said U.S. SKYCLARYS revenue was “lumpy” due to inventory build at the end of Q4 and fewer buying weeks in Q1, while patient demand was “right on par.” She added that many patients are coming from physicians who may only write one prescription for Friedreich’s ataxia and that these patients tend to be older and slower-progressing than initially predicted, requiring more time to identify. Viehbacher said ex-U.S. strategy includes early access programs during reimbursement negotiations, which can create revenue “lumpiness” when reimbursement decisions convert multiple patients from “zero revenue” to reimbursed status.

Spinraza high-dose rollout and SMA franchise plans

Viehbacher said the new high-dose Spinraza has been approved in the U.S., Japan, and Europe, with patients already on the new regimen. He said early feedback has been positive and that Biogen has heard anecdotal reports of “switch backs,” arguing that improved efficacy could help competitiveness in spinal muscular atrophy (SMA).

Alaimo said Spinraza high-dose has been available in the U.S. for less than a month and that “20%” of her patient base has already submitted start forms to move to the high-dose regimen. She also said Biogen is seeing switches from competitors and add-on use in patients who received Zolgensma. Viehbacher added that in Germany, roughly 20% of patients have converted to high-dose Spinraza.

Viehbacher also linked the SMA franchise outlook to future administration improvements and pipeline progress, citing Biogen’s acquisition of Alcyone as a potential avenue to address intrathecal administration burdens and pointing to salanersen’s development as a “once yearly” intrathecal option. Singhal said new data from salanersen showed durable benefit over one year in children previously treated with gene therapy and noted the first patient has been dosed in the pivotal STELLAR-1 study in treatment-naïve pre-symptomatic infants.

Pipeline catalysts and BIIB080 focus

Singhal described 2026 as a year with “several data-related inflection points” and said Biogen expects a multi-year registrational data flow beginning later in 2026 and extending through the end of the decade. She cited upcoming milestones across litifilimab (SLE and CLE), felzartamab (including AMR), and zorevunersen (Dravet syndrome), and noted a PDUFA date for Leqembi IQLIK initiation “next month.”

Analysts asked repeatedly about BIIB080, an antisense oligonucleotide targeting tau. Singhal said prior extracellular antibody approaches have not worked, and she framed BIIB080 as differentiated by the potential to target intracellular and extracellular tau. She said Biogen observed tau reduction in a small phase I-B trial that supported moving into a proof-of-concept study, and that the CELIA readout expected “mid-year” will test whether tau reduction translates into clinical benefit on cognition. Singhal said the primary endpoint is CDR Sum of Boxes and that the study includes multiple doses and two treatment paradigms (quarterly and every six months). Viehbacher said the company will evaluate the “totality” of data, including tau PET, and that BIIB080 remains a “pioneering study” without clear precedent for how much tau reduction or what magnitude of cognitive effect would be sufficient to advance.

Singhal also said Biogen is exploring delivery options beyond intrathecal dosing in preclinical and research work, and noted that the Alcyone acquisition provides another potential avenue for delivery.

On litifilimab, Singhal said Biogen expects two phase III SLE trials to read out this year and a CLE trial to read out early next year. She said the company does not typically comment on filing strategy but currently views the program as a “package,” and that if one SLE trial were positive and the other negative, Biogen would assess the “totality of data,” citing precedent in the field. She also noted litifilimab received breakthrough designation for CLE earlier in the year and that Biogen presented additional positive phase II CLE data.

Apellis acquisition: strategic rationale and expected financial impact

Viehbacher said the pending Apellis acquisition would expand Biogen’s commercial growth portfolio with two marketed products, Syfovre and Empaveli, describing them as one molecule with three indications and two brands. He said Biogen expects the acquisition to be accretive in 2027 and to “materially” increase the company’s EPS outlook over the coming years, while emphasizing that the transaction had not yet closed and limiting details.

Kramer said the Apellis transaction is expected to close in the second quarter of 2026 and would be funded with $3.6 billion of cash and $2 billion in bank borrowings, which Biogen expects to repay by the end of 2027. She said Biogen expects approximately $120 million to $130 million of impact to non-GAAP other income/expense in 2026, driven largely by financing and foregone interest income, and reiterated expectations for non-GAAP EPS accretion in 2027. The company said it will provide 2026 guidance inclusive of Apellis when reporting Q2 results after the close.

Executives discussed the strategic fit of Apellis’ assets with Biogen’s immunology and rare disease focus. Viehbacher described geographic atrophy as an immune-driven disease and said the goal of treatment is to slow lesion progression rather than focus initially on visual acuity. On Empaveli, he said adding Apellis would bring an established nephrology presence and relationships that could support Biogen’s broader nephrology franchise, including felzartamab, where he said Biogen’s conviction is growing ahead of initial data.

During Q&A, executives addressed Syfovre’s place in geographic atrophy and the competitive backdrop. Singhal said lesion growth is the “gold standard” endpoint in the disease and cited Syfovre data showing a “42%” statistically significant reduction in lesion growth, along with five-year long-term data presented by Apellis suggesting progression could be slowed by 1.5 years. Viehbacher added that having five-year data creates a “data moat” in a slowly progressive disease where physician and patient confidence in long-term safety and outcomes is important.

Alaimo said geographic atrophy remains significantly under-treated, citing a “1.5 million” patient population and “only 20%” treated, and said patient activation and education will be critical. She said Biogen expects to spend on direct-to-consumer and TV advertising after the deal closes, adding that Biogen’s existing patient services infrastructure and launch experience across multiple therapeutic areas could provide support and potential synergies.

About Biogen NASDAQ: BIIB

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.